Roivant Sciences: $7bn Televant Sale Sets It Up For Long-Term Success [Seeking Alpha]
Roivant Sciences Ltd. (ROIV)
Company Research
Source: Seeking Alpha
The company has a differentiated drug development pipeline targeting multi-billion dollar indications, thanks to its unique "Vant" subsidiaries and some smart dealmaking. Last October, Swiss Pharma giant Roche paid $7bn to acquire Televant, and acquire U.S. and Japanese rights to late stage autoimmune drug RVT-3101. This has give Roivant a $6bn war chest to do what it does best - make strategic investments into promising drug development opportunities. With several major data readouts due this year, plus a potential approval for topical cream Vtama in atopic dermatitis, Roivant stock appears to have strong upside prospects in 2024. Investment Thesis I last covered Roivant Sciences Ltd. NASDAQ: ROIV ) in a note for Seeking Alpha back in May last year, giving the company a buy recommendation, based on an intriguing and differentiated drug development pipeline targeting multi-billion dollar indications, with multiple significant data catalysts in play. 10 months on, Roivant
Show less
Read more
Impact Snapshot
Event Time:
ROIV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ROIV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ROIV alerts
High impacting Roivant Sciences Ltd. news events
Weekly update
A roundup of the hottest topics
ROIV
News
- Roivant and Kinevant Sciences Complete Enrollment in RESOLVE-Lung, a Phase 2 Study Evaluating Namilumab for Chronic Pulmonary SarcoidosisBusiness Wire
- Roivant Sciences: Cashing In On Vants And Ventures [Seeking Alpha]Seeking Alpha
- OSR Holdings and SillaJen have entered into a Memorandum of Understanding to collaboratively pursue the development of innovative therapeutics and enter the U.S. market [Yahoo! Finance]Yahoo! Finance
- Roivant Sciences Ltd. (NASDAQ: ROIV) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $18.00 price target on the stock.MarketBeat
- Arbutus Biopharma jumps after patent victory in fight with Moderna [Seeking Alpha]Seeking Alpha
ROIV
Earnings
- 2/13/24 - Beat
ROIV
Sec Filings
- 4/26/24 - Form 4
- 4/26/24 - Form 4
- 4/26/24 - Form 4
- ROIV's page on the SEC website